ConductScience.org, home

Paper36840482

Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.

Hong X and 5 others. Immun Inflamm Dis, 2023. Cited by 21 papers, by iCite.

Cite this record

ConductScience Library. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Papers, record 36840482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36840482

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
PubMed
Journal
Immun Inflamm Dis
PubMed
Year
2023
PubMed
Publication types
Systematic Review, Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
2.78
iCite
Revised in PubMed
2025-06-26
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hong XXuezhi
2Xiao YYanhuahttps://orcid.org/0000-0002-8965-1111
3Xu LLiyan
4Liu LLei
5Mo HHailu
6Mo HHanyou

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Arthritis, RheumatoidMajor topic
Biological ProductsMajor topic
Hepatitis BMajor topic
Janus Kinase InhibitorsMajor topic
Humans
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Hepatitis B virus
Interleukin-6
Rituximab
Tumor Necrosis Factor-alpha

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
81760298National Natural Science Foundation of ChinaPubMed
2020GXNSFBA297149Natural Science Foundation of Guangxi ProvincePubMed

Source PubMed

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136840482Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.Immun Inflamm Dis2023https://conductscience.org/library/papers/36840482PubMed
221719446Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.Ann Rheum Dis2011https://conductscience.org/library/papers/21719446PubMed
332051458Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis.Sci Rep2020https://conductscience.org/library/papers/32051458PubMed
431117160Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.Int J Rheum Dis2019https://conductscience.org/library/papers/31117160PubMed
525447850American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology2015https://conductscience.org/library/papers/25447850PubMed
633028756Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid Arthritis.Tohoku J Exp Med2020https://conductscience.org/library/papers/33028756PubMed
724698305Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Int J Rheum Dis2016https://conductscience.org/library/papers/24698305PubMed
825381975Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients.Drug Dev Res2014https://conductscience.org/library/papers/25381975PubMed
928160426Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.Int J Rheum Dis2017https://conductscience.org/library/papers/28160426PubMed
1025613809Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.Hepatology2015https://conductscience.org/library/papers/25613809PubMed
1128427875EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017https://conductscience.org/library/papers/28427875PubMed
1226879359Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.J Rheumatol2016https://conductscience.org/library/papers/26879359PubMed
1329611409Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.Yonsei Med J2018https://conductscience.org/library/papers/29611409PubMed
1421246383Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.J Gastroenterol2011https://conductscience.org/library/papers/21246383PubMed
1528529116Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis.Joint Bone Spine2017https://conductscience.org/library/papers/28529116PubMed
1625447852American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology2015https://conductscience.org/library/papers/25447852PubMed
1720535784Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.Arthritis Care Res (Hoboken)2010https://conductscience.org/library/papers/20535784PubMed
1830338649Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Int J Rheum Dis2019https://conductscience.org/library/papers/30338649PubMed
1920668905Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.Mod Rheumatol2011https://conductscience.org/library/papers/20668905PubMed
2024495663Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.Eur J Intern Med2014https://conductscience.org/library/papers/24495663PubMed

See all 35 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42370076Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.EULAR Rheumatol Open2026https://conductscience.org/library/papers/42370076PubMed
423629432024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.Int J Rheum Dis2026https://conductscience.org/library/papers/42362943PubMed
41239737Liver-joint axis: Hepatitis B virus as a contributor to rheumatoid arthritis pathogenesis.Virulence2025https://conductscience.org/library/papers/41239737PubMed
40385464Treatment of Atopic Dermatitis with Upadacitinib in a Patient During Hepatitis C Activity Period.J Asthma Allergy2025https://conductscience.org/library/papers/40385464PubMed
39998600
Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters.
Clin Rheumatol2025https://conductscience.org/library/papers/39998600PubMed
39850429Contradictory Mechanisms of rheumatoid arthritis and hepatitis B virus infection activation.Heliyon2025https://conductscience.org/library/papers/39850429PubMed
39381733Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.Reumatologia2024https://conductscience.org/library/papers/39381733PubMed
39014279Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.Dermatol Ther (Heidelb)2024https://conductscience.org/library/papers/39014279PubMed
38809367Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy.Infect Dis Ther2024https://conductscience.org/library/papers/38809367PubMed
38586821Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant.ACG Case Rep J2024https://conductscience.org/library/papers/38586821PubMed
38257778The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.Viruses2024https://conductscience.org/library/papers/38257778PubMed
38216802Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.Am J Clin Dermatol2024https://conductscience.org/library/papers/38216802PubMed
36840482Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.Immun Inflamm Dis2023https://conductscience.org/library/papers/36840482PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36840482

GET https://conductscience.org/api/papers/v1/36840482/references?page=2